Domestic violence happens 145 times every hour in the U.S. It affects more women than breast cancer, lung cancer and ovarian cancer combined. As part of Domestic Violence Awareness Month in October, The Allstate Foundation has partnered with actress Rosario Dawson for the Purple Purse campaign to raise awareness of domestic abuse and the role finances play in helping survivors break free from violence. In its third year, The Allstate Foundation Purple Purse campaign has pledged to donate up to $350,000 to the YWCA for programs that help domestic violence survivors gain the financial knowledge and resources needed to live independently.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62951-allstate-foundation-rosario-dawson-fight-domestic-violence-purple-purse
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Today in New York, Avon Foundation for Women Honorary Chairperson Reese Witherspoon recognized Breast Cancer Awareness Month at the 2011 Global Breast Cancer Congress – where she launched a new Avon Foundation for Women-funded global breast cancer scholarship program – and at the Avon Walk for Breast Cancer – where she presented more than $9.1 million in grants to New York-area breast cancer programs.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46209-reese-witherspoon-announces-avon-global-breast-cancer-scholars-program
Global health service company Cigna is on a mission: to get HopeLab’s cancer-fighting game app Re-Mission 2: Nanobot’s Revenge onto the phones and tablets of every young cancer patient in the world. The free app is available for Android and iOS (Apple) mobile devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/62267-cigna-hopelab-re-mission-2-mobile-app
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
Featuring a noted cancer researcher, animal behaviorists and a 14-year-old entrepreneur who developed a new product to ease pets’ separation anxiety, Purina’s second Better With Pets Summit emphasized how technology and scientific advances are leading to a brighter future with our pets. The daylong event, Tuesday, in New York City featured 15 expert presentations on scientific, nutritional and behavioral innovations to help better understand why our lives are better with pets.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325551-purina-better-with-pets-summit-2014/
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
